ClinicalTrials.gg
CompletedNCT03329209Updated Sep 6, 2019Results posted

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

A Phase 1 interventional study of Vedolizumab in Colitis, Ulcerative and Crohn Disease, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
33rd of 38
16 · median 110
Started
2018
with 1 other
Phase 1
2 of 38
none open now
Registered
22nd of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 33rd largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 1, and was the 22nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have ulcerative colitis (UC) or Crohn's disease (CD). This study will look at the PK, safety, and tolerability of vedolizumab following a single intravenous infusion of vedolizumab IV in healthy adult Chinese participants.

The study will enroll approximately 16 participants. All participants will be assigned to receive a single dose of vedolizumab IV 300 mg on Day 1.

This single center trial will be conducted in China. The overall time to participate in this study is approximately 7 months. Participants will make multiple visits to the clinic, and will be contacted by telephone, 6 months after single dose of study drug for a follow-up safety survey assessment.

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant weighs at least 50 kilogram (kg) and has a (BMI) from 19.0 to 26.0 kilogram per square meter (kg/m\^2) inclusive at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Has one or more positive response on the progressive multifocal leukoencephalopathy (PML) subjective symptoms checklist at Screening or before dosing on Day 1.
  2. Has had a surgical procedure requiring general anesthesia within 30 days before the initial Screening Visit or is planning to undergo a surgery that requires general anesthesia during the study period (through Final Visit/Day 127).
  3. For participants who are negative for surface antigen (HBsAg) but are positive for either surface antibodies and/or core antibodies, hepatitis B virus Deoxyribonucleic Acid (DNA) polymerase chain reaction will be performed and any result that meets or exceeds detection sensitivity will be excluded.
  4. Has poor peripheral venous access.
  5. Has a with Fridericia correction method (QTcF) greater than (>) 430 millisecond (ms) (males) or >450 ms (females) or PR outside the range 120 to 220 ms, confirmed with 1 repeat testing within a maximum of 5 minutes, at the Screening Visit or Check-in (Day -1).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg

    Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.

    Drug: Vedolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Serum Concentration for Vedolizumab

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

  2. AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

  3. AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

Secondary outcomes

  1. Percentage of Participants With Positive Anti-vedolizumab Antibody (AVA)

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

  2. Percentage of Participants With Positive Neutralizing AVA

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 127) post-dose

07

Results

Posted Sep 6, 2019

Participant flow

Participants took part in the study at 1 investigative site in China from 05 March 2018 to 05 September 2018.

Participant flow — Overall Study
MilestoneVedolizumab 300 mg
Started16
Completed16
Not completed0

Outcome measures

PrimaryCmax: Maximum Observed Serum Concentration for Vedolizumab
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Cmax: Maximum Observed Serum Concentration for Vedolizumab
microgram per milliliter (mcg/mL)Vedolizumab 300 mg
Cmax: Maximum Observed Serum Concentration for Vedolizumab136.4120 ± 15.90597
PrimaryAUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · day*microgram per milliliter(day*mcg/mL)
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab
day*microgram per milliliter(day*mcg/mL)Vedolizumab 300 mg
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab2342.5803 ± 294.75822
PrimaryAUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Geometric mean · day*mcg/mL
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab
day*mcg/mLVedolizumab 300 mg
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab2377.6463 ± 296.46345
SecondaryPercentage of Participants With Positive Anti-vedolizumab Antibody (AVA)
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-vedolizumab Antibody (AVA)
percentage of participantsVedolizumab 300 mg
Percentage of Participants With Positive Anti-vedolizumab Antibody (AVA)37.5
SecondaryPercentage of Participants With Positive Neutralizing AVA
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 127) post-dose
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Neutralizing AVA
percentage of participantsVedolizumab 300 mg
Percentage of Participants With Positive Neutralizing AVA37.5

Adverse events

Collected over Treatment emergent adverse events (TEAE) are adverse events that started after the infusion of study drug and no more than Day 127. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg0/16 (0%)0/16 (0%)6/16 (37.5%)
Most frequent other events
Most frequent other events
EventVedolizumab 300 mg
Upper respiratory tract infectionInfections and infestations4/16
LeukocyturiaRenal and urinary disorders2/16
Blood creatine phosphokinase increasedInvestigations1/16
Hepatic enzyme increasedInvestigations1/16

Baseline characteristics

The safety analysis set consisted of all participants who were enrolled and received 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mg
Mean30.4 ± 6.22
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mg
Female7
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vedolizumab 300 mg
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mg
China16
Height
Height(centimeter (cm))Vedolizumab 300 mg
Mean167.00 ± 7.474
Weight
Weight(kilogram (kg))Vedolizumab 300 mg
Mean63.83 ± 6.448
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Vedolizumab 300 mg
Mean22.87 ± 1.622
08

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing 100034, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2018, 4 months.

Results were first posted in Sep 2019, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 1, 2017
StartActual
Mar 5, 2018
Primary completionActual
Jul 26, 2018
CompletionActual
Sep 5, 2018
Results first posted
Sep 6, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03329209
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 1, 2017
Start date
Mar 5, 2018
Primary completion
Jul 26, 2018
Completion
Sep 5, 2018
Results posted
Sep 6, 2019
Last update
Sep 6, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion